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THE FOOD AND DRUG
ADMINISTRATION AND THE
PHARMACY PROFESSION: PARTNERS
TO ENSURE THE SAFETY AND
EFFICACY OF PHARMACOGENOMIC
THERAPY
JENNIFER E. SPRENG*
INTRODUCTION
In 1998, the Food and Drug Administration (FDA) approved the drug
thalidomide for the treatment of leprosy patients.' The decision was notable
because, in response to serious birth defects in Europe associated with use of the
drug,2 Congress had reformed the Food, Drug, and Cosmetic Acte in 1962 to extend
the FDA's authority to use a pre-market approval process to ensure the safety and
efficacy of drugs. 4 In 1998, as a result of that pre-market approval process, the
sponsor of thalidomide agreed to strategies to limit the drug's distribution through
approved pharmacists pursuant to strict procedures designed to protect pregnant
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1. Letter from Murray M. Lumpkin, Deputy Ctr. Dir., Ctr. for Drug Evaluation & Research, to
Steve Thomas, Celgene Corp. (July 16, 1998), available at http://www.accessdata.fda.gov/
drugsatfda-docs/appletter/1998/207851tr.pdf.
2. See Ctr. for the Evaluation of Risks to Human Reproduction, U.S. Dep't of Health & Human
Servs., Common Concerns-Thalimodine, http://cerhr.niehs.nih.gov/common/thalidomide.html (last
visited Feb. 20, 2010) (describing the history of the use of thalidomide and its relationship to birth
defects).
3. Federal Food, Drug, and Cosmetic Act, 21 U.S.C. §§ 301-399 (2006).
4. Drug Amendments of 1962, Pub. L. No. 87-781, §§ 101-102, 104, 201, 76 Stat. 780, 780-82,
784-85, 792-93 (codified at 21 U.S.C. §§ 355, 374 (2006)).
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women and women who might become so. 5 The sponsor also agreed to create a
register of all patients using the drug and require that all physicians and
pharmacists have patients execute a specific informed consent document.
6
Before 2007, pharmaceutical companies sometimes felt pressure from the
FDA to establish special distribution systems and other post-marketing strategies
on a "voluntary basis" as a condition of approving a new drug application that
otherwise might not be safe.7 That year, Congress gave the FDA formal statutory
authority to approve otherwise-unsafe drugs if a "risk evaluation and mitigation
strategy... ensure[d] that the benefits of the drug outweigh[ed] the risks of the
drug.",8 The FDA may now impose a risk mitigation strategy that includes allowing
only "specially certified" pharmacists to dispense a drug9 or requiring that a drug
be "dispensed to patients with evidence or other documentation of safe-use
conditions, such as laboratory test results."' 0
The statute goes hand-in-hand with more frequent approval and satisfactory
post-marketing supervision of drugs that are safe and/or effective only for those
with a specific genetic profile because the FDA can now recommend or require a
5. Margaret Gilhooley, When Drugs Are Safe for Some but Not Others: The FDA Experience and
Alternatives for Products Liability, 36 HOuS. L. REV. 927, 943 (1999); see also Celgene Corp.,
Thalomid (Thalidomide) Capsules: Revised Package Insert (Jul. 15, 1998), available at
http://www.cancerconsultants.com/druginserts/fhalidomide.pdf [hereinafter Thalidomide Package
Insert] ("Under [the] restricted distribution program, only prescribers and pharmacists registered with
the program are allowed to prescribe and dispense [thalidomide].").
6. Gilhooley, supra note 5, at 943-44. The drug's package insert explains these requirements and
contains numerous "black box" warnings as to the serious risks of birth defects from thalidomide use,
even if a woman takes only one capsule. Thalidomide Package Insert, supra note 5, at 1.
7. See, e.g., Tilo Mandry, Legal Implications of Pharmacogenomics Regarding Drug Trials, Drug
Labeling, and Genetic Testing for Drug Prescription: An International Approach, 59 FOOD & DRUG L.J.
519, 532-33 (2004) (listing restrictions to assure safe use of the drug clozapine); Letter from Robert A.
Sausville, Dir. of Div. of Case Mgmt., Ctr. for Biologics Evaluation & Research, to Mary Ann Lamb,
Vice President of Reg. Aff, Talecris Biotherapeutics, Inc. (Jul. 6, 2009), available at
http://www fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatorylnformation/Compliance
Activities/Enforcement/UntitledLetters/ucml73449.htm (lamenting that, because post-market reporting
is voluntary, it is difficult to track adverse reactions to the drug Gamunex); Letter from Christine Hemler
Smith, Regulatory Review Officer, Dep't of Health & Human Servs., to Mark R. Szewczak, Dir. of
Promotional Reg. Aff., AstraZeneca, LP (Dec. 21, 2004), available at http://www.fda.gov/downloads/
Drugs/GuidanceComplianceRegulatorylnformation/EnforcementActivitiesbyFDA/WamingLettersandN
oticeofViolationLetterstoPharmaceuticalCompanies/ucm05465 7.pdf (referring to AstraZeneca's
voluntary special distribution program for the drug Crestor).
8. Food and Drug Administration Amendments Act of 2007, Pub. L. No. 110-85, sec. 90 1(b), §
505-1(a)(1), 121 Stat. 823, 926 (codified at 21 U.S.C.A. § 335-1 (West Supp. 2009)). Prior to this
statutory authority, the FDA had taken the position that it was entitled to require manufacturers to follow
strategies to mitigate potential adverse effects even when a drug was prescribed by a physician. See 21
C.F.R. §§ 208.20, .24 (2007) (providing details on the contents of medication guides that the FDA
required some drug manufacturers to distribute with its drugs).
9. 21 U.S.C.A. § 355-1(f)(3)(B).
10. Id. § 355-1(f)(3)(D).
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genetic test as part of a risk mitigation strategy." The FDA does have less intrusive
means of protecting the public.' 2 For example, it can require manufacturers to
include conspicuous "black box" warnings on package inserts, as well as lists of
contraindications and adverse reactions in patients with specific genotypes.'
3
Black box warnings, however, like other physician-targeted approaches to
ensuring drug safety, may be insufficient because physicians do not always read
them. 14 Similarly, both doctors and hospitals have resisted adopting technologies,
such as computerized physician order entry, that would reduce medication error.' 5
Physicians are so engrained in the habit of prescribing drugs "off-label," or for
conditions and in doses other than those for which the FDA approved the drug, that
the habit may be very difficult to break. 16 Further, physicians are behind the ball in
their understanding of how to use genetic information and interpret genetic tests
when making prescription and dosing decisions.' 7 The FDA will need different risk
management partners.' 8
11. Id.; see, e.g., Press Release, U.S. Food & Drug Admin., FDA Approves Updated Warfarin
(Coumadin) Prescribing Information: New Genetic Information May Help Providers Improve Initial
Dosing Estimates of the Anticoagulant for Individual Patients (Aug. 16, 2007), available at
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucml 08967.htm (announcing
approval of a labeling change for the blood-thinning drug Coumadin to explain that patients' genetic
makeup may influence their reactions to the drug, and encouraging health care providers to use genetic
testing to improve their dosing of the drug).
12. See, e.g., 21 C.F.R. § 201.56-57 (2009) (allowing prescription drug box warnings that contain
"contradictions" to explain situations in which the drug should not be used).
13. Id.
14. See, e.g., Happel v. Wal-Mart Stores, Inc., 737 N.E.2d 650, 652-53 (I11. App. Ct. 2000)
(describing that the prescribing physician was unaware of the potential fatal reaction, which could have
been cured by his reading the label on the drug), The learned intermediary doctrine allows
manufacturers to rely on physicians to warn patients about the risks of medications, which means that as
long as the warning appears on a package insert that a physician may never consult, the manufacturer
may have no tort liability. Mark A. Rothstein, Liability Issues in Pharmacogenomics, 66 LA. L. REV.
117, 119 (2005). See generally Teresa Kelton, Pharmacogenomics: The Re-Discovery of the Concept of
Tailored Drug Therapy and Personalized Medicine, HEALTH LAW., Jan. 2007, at 1, 5 (describing the
concept of "personalized medicine," which gives physicians more leeway in how to prescribe certain
drugs to patients); Mandry, supra note 7, at 531-32 (describing FDA warning requirements placed on
drug manufacturers).
15. Amy Jurevic Sokol & Christopher J. Molzen, The Changing Standard of Care in Medicine: E-
Health, Medical Errors, and Technology Add New Obstacles, 23 J. LEGAL MED. 449, 467-68, 486-87
(2002) (arguing that in time, failure to embrace health technologies will harm health care providers by
exposing them to potential malpractice liability, and that, while tort liability can be a useful regulatory
tool, it is not the ideal first line defense against medication error).
16. See, e.g., Lars Noah, The Coming Pharmacogenomics Revolution: Tailoring Drugs to Fit
Patients' Genetic Profiles, 43 JURIMETRICS 1, 13-14 (2002) (noting that "the FDA has long accepted the
legitimacy of off-label prescribing" as a means of personalizing medical therapy).
17. See Hong-Guang Xie & Felix W. Frueh, Pharmacogenomics Steps Toward Personalized
Medicine, 2 PERSONALIZED MED. 325, 332 (2005) (explaining that the incorporation of
pharmacogenomic testing into patient care has been slow partly due to resistance to using new
technologies and methods). The full extent of "personalized medicine," which tailors treatment
according to a person's genetic makeup, is beyond the scope of this Article. This Article is limited to
2010]
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Pharmacists can help. While medical schools provide surprisingly limited
training in drug therapy, 19 pharmacists devote their entire professional education to
the subject.20 Both federal and state statutes, as well as their own professional
aspirations, encourage pharmacists to participate in drug therapy decisions and
counsel customers about risks, contraindications, and appropriate use of
medications.21 Pharmacists could refuse to dispense a drug without reviewing a
report of results from a simple genetic test-the "laboratory test" of the Food,
Drug, and Cosmetic Act's plain language22-resulting in a decrease in the number
of adverse reactions as well as assisting in the identification of drugs that are likely
to be ineffective for that particular patient.23 Widespread computer use in the
profession would alert a pharmacist of the need to review the report and alert the
physician about the potential for genetic variation in outcomes from use of the
drug.24 Louisiana State University Professor of Law, Science and Public Health,
Michael Malinowski predicts that as innovative pharmaceuticals targeted at specific
genetic profiles appear on the market, instead of "making doctors and nurses
discussing means of limiting adverse reactions to medications and identifying ineffective drugs prior to
treatment.
18. See infra Part III.
19. See Michael J. Malinowski & Robin JR. Blatt, Commercialization of Genetic Testing Services:
The FDA, Market Forces, and Biological Tarot Cards, 71 TUL. L. REV. 1211, 1245 n.l 10 (1997)
(discussing primary care providers' lack of knowledge about genetics); Rodolfo Rodriguez et al.,
Changing the Countenance of Pharmacology Courses in Medical Schools, 18 TRENDS IN
PHARMACOLOGICAL SCI. 314, 314-18 (1997) ("[l]ncreasing concern has recently been expressed about
the extent to which ... pharmacology courses provide medical students with the adequate knowledge,
skills and expertise required to contend with contemporary therapeutic problems.").
20. Gary G. Cacciatore, Computers, OBRA 90 and the Pharmacist's Duty to Warn, 5 J. PHARMACY
& L. 103, 103-05 (1995). Experts believe a serious limitation to the utility of genetic testing in drug
prescribing is the failure of medical schools in the 1990s to provide genetics training, a problem now not
easily corrected. See Malinowski & Blatt, supra note 19, at 1245 & n. 110, 1246 (noting that in the
1990s, doctors were merely getting up to speed on genetics and were unable to keep up with patient
demand on the subject, and that more education focusing on genetic technologies is needed); Gary E.
Marchant, Personalized Medicine and the Law, ARIZ. ATT'Y, Oct. 2007, at 12, 16 (explaining that
current health care professionals and institutions resist training their physicians and pharmacists in
genetics testing and instead refuse to offer the tests). Pharmacists still need additional training to do this
work. See Marchant, supra, at 16. But the comparative depth of their drug therapy training makes them
more likely to get up to speed more quickly than physicians. See Cacciatore, supra note 20, at 104-05
(detailing the training of pharmacists).
21. See infra notes 44-59 and accompanying text.
22. See supra notes 9-10 and accompanying text.
23. See Kelton, supra note 14, at 3, 6 (explaining that genetic information provides health care
providers with a better picture of which drugs would be effective for particular patients); Xie & Frueh,
supra note 17, at 326, 331 (noting that genetic variations in patients may result in adverse reactions to
certain drugs).
24. See Cacciatore, supra note 20, at 114-15 (describing the usefulness of computers to health care
providers).
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assume th[e] entire burden, it is likely that pharmacists and non-physician
clinicians will be stepping into an expanded role in the health care process.
'2 5
This Article will argue that pharmacists are well-positioned to serve as a
backstop to physicians' prescription decisions when a particular drug is either
unsafe or ineffective for a patient with a certain genetic makeup. Part I of this
Article will describe recent developments in pharmacy practice that make
pharmacists well-suited for that role.26 Part II will discuss the FDA's regulatory and
practical authority over pharmacogenomics.2 7 Part III will develop a legal
framework to link drug approval to the practice of pharmacy, 28 concluding that,
with respect to drugs unsuitable for patients with specific genotypes, either
regulation or tort law should require that pharmacists confirm results of genetic
tests prior to dispensing those drugs.29
The model this Article presents will require some suspension of disbelief, at
least in the short term. 30 The FDA regulates only a few genetic tests, 3 1 and others
are of questionable validity,32 which make them unreliable for dosing and
dispensing decisions.33 Testing is not currently a viable option in emergencies,34
25. Michael J. Malinowski, Law, Policy, and Market Implications of Genetic Profiling in Drug
Development, 2 HOUS. J. HEALTH L. & POL'Y 31, 55 (2002).
26. See infra Part 1.
27. See infra Part I1.
28. See infra Part III.
29. See infra Part III.D.
30. Malinowski, supra note 25, at 52 ("The day when the neighborhood pharmacist routinely tailors
commercially available pharmaceuticals to account for each person's [genetic] idiosyncrasies may be
decades removed.").
31. See, e.g., 21 C.F.R. §§ 809.3, .10, .20, .30 (2009) (regulating in vitro diagnostic products and
analyte specific regents); CTR. FOR DEVICES & RADIOLOGICAL HEALTH ET AL., U.S. DEP'T OF HEALTH
& HUMAN SERVS., GUIDANCE FOR INDUSTRY AND FDA STAFF: PHARMACOGENETIC TESTS AND
GENETIC TESTS FOR HERITABLE MARKERS 3, 5-6 (2007), available at http://www.fda.gov/downloads/
MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucmO7l075.pdf [hereinafter FDA
GUIDANCE ON PHARMACOGENETIC TESTS] (describing general requirements for certain pharmacogentic
and genetic tests); CTR. FOR DEVICES & RADIOLOGICAL HEALTH & CTR. FOR BIOLOGIC EVALUATION &
RESEARCH, U.S. DEP'T OF HEALTH & HUMAN SERVS., DRAFT GUIDANCE FOR INDUSTRY, CLINICAL
LABORATORIES, AND FDA STAFF: IN VITRO DIAGNOSTIC MULTIVARIATE INDEX ASSAYS 3, 7 (2007),
available at http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/Guidance
Documents/ucm071455.pdf (covering regulation of a specific type of genetic test, called in vitro
diagnostic multivariate index assays or IVDMIAs). The terms pharmacogenomics and
pharmacogenetics are not the same. Nat'l Ctr. for Biotechnology Info., One Size Does Not Fit All: The
Promise of Pharmacogenomics, http://www.ncbi.nlm.nih.gov/About/primer/pharm.html (last visited
Feb. 20, 2010). "Pharmacogenetics refers to the study of inherited differences (variation) in drug
metabolism and response." Id. The FDA regulates both similarly and so the Guidance applies to both
types of tests. FDA GUIDANCE ON PHARMACOGENETIC TESTS, supra, at I.
32. See, e.g., § 809.30(e) (requiring that reports must contain a notification that the test is not
approved by the FDA).
33. See Malinowski, supra note 25, at 53-54 (noting that "homebrew tests" conducted by drug
manufacturers escape FDA regulation, and that manufacturers often lack data to support their utility);
2010]
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and often tests are prohibitively expensive.35 Drugs and genetic tests may not
obtain simultaneous FDA approval,36 and criticism over high prices and potential
antitrust violations will discourage manufacturers from "bundling" drugs and
tests.37 Some manufacturers are less than enthusiastic about developing drugs
limited to patients with specific genetic profiles; the costs of getting a drug on
pharmacy shelves make "blockbuster" drugs the preferred products in the
pharmaceutical industry.38 Nevertheless, several companies claim that within only a
year they may have full genome sequencing services on the market39 -albeit for
prices that in the short term only a few will be able to afford 40 -which would
increase the potential viability of a "small business model" of drug development
and manufacture. 4'
Of course, the mere fact that a "solution" addresses only part of a problem is
not a reason to neglect pursuing it. Point-of-sale screening can keep valuable
medications such as Coumidin on the market even though they cause adverse
Mandry, supra note 7, at 530 (explaining that genetic testing is not the only indicator of suitability of a
drug for a particular patient).
34. Mandry, supra note 7, at 530. This may change as complete human genome sequences become
available to providers via electronic medical records, but the many complex legal and technological
challenges facing both projects combine to make the possibility unlikely in the foreseeable future. See
generally Keith A. Bauer, Privacy and Confidentiality in the Age of E-Medicine, 12 J. HEALTH CARE L.
& POL'Y 47 (2009) (discussing the general privacy and confidentiality concerns associated with the
growing use of electronic medical records); Kristen Rosati, Using Electronic Health Information for
Pharmacovigilance: The Promise and the Pitfalls, J. HEALTH & LIFE SCI. L., July 2009, at 171, 182-215
(discussing privacy issues with the use of genetic testing and other health data).
35. See Wendy L. McGoodwin, Genetic Testing in Life and Disability Insurance, 28 THE BRIEF 24,
28 (1998) ("Because most genetic tests are quite new, they are now prohibitively expensive."); Perry W.
Payne, Jr., Currents in Contemporary Ethics: For Asians Only? The Perils of Ancestry-Based Drug
Prescribing, 36 J. L. MED. & ETHICS 585, 585 (2008) (noting the "cost concerns" related to "genetic
testing of all people").
36. See, e.g., Marchant, supra note 20, at 16 ("[M]ost genetic tests currently require no regulatory
approval in the United States.").
37. Noah, supra note 16, at 21-22.
38. See Kelton, supra note 14, at 7 (explaining that advances in pharmacogenetics will likely
fragment the pharmaceutical market and the blockbuster paradigm adopted by big pharmaceutical
companies).
39. Getting Personal: The Promise of Cheap Genome Sequencing, THE ECONOMIST, Apr. 16, 2009,
available at http://www.economist.com/specialreports/displaystory.cfn?STORY-ID=1 3437974
[hereinafter Getting Personal] (discussing a number of global consumer-genomics companies
attempting to provide personal genetic testing, including one that expects to offer complete genome
sequencing within a year); John Markoff, I.B.M Joins Pursuit of $1,000 Personal Genome, N.Y. TIMES,
Oct. 6, 2009, at D2, available at http://www.nytimes.com/2009/l0/06/science/06dna.html (reporting that
seventeen startup companies are preparing to offer full genome sequencing).
40. Markoff, supra note 39 ("Sequencing the human genome now costs $5,000 to $50,000 . .
41. Id. (predicting the price of human genome sequencing will fall below $100). It is possible that
as prices decline over time, drug companies might choose to offer genome sequencing services for free
in order to market personalized medications. Getting Personal, supra note 39.
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reactions in patients with a specific gene mutation.42 A partnership between the
FDA and the pharmacy profession will take advantage of current professional
resources as well as provide a foundation for safe distribution of drugs in the
future.
43
I. PHARMACY PROFESSION: YOU'VE COME A LONG WAY, BABY
The pharmacy profession has come a long way. In the early 20th century,
pharmacists were still primarily compounders: professionals who prepared drugs
themselves." In 1951, Congress passed the Prescription Drug Amendments to the
Food, Drug, and Cosmetic Act,45 thereby separating drugs available only via
46 otaprescription from those available without a prescription. As a result of that
legislation, pharmacists became the "gatekeeper" to the nation's drug supply, with
a monopoly over distribution of prescription drugs.
47
More recently, the pharmacy profession took another leap forward.48 The
Omnibus Budget Reconciliation Act of 199049 (OBRA 90) imposed several duties
on pharmacists dispensing to Medicaid patients,5 ° which most states adopted for all
patients. 51 Among its requirements were that pharmacists counsel customers about
42. See Press Release, Food & Drug Admin., FDA Clears Genetic Lab Test for Warfarin
Sensitivity (Sept. 17, 2007), available at http://www.fda.gov/NewsEvents/Newsroom/Press
Announcements/2007/ucm108984.htm (announcing the clearance of a test to screen for two genes that
trigger sensitivity to warfarin); U.S. Office of Personnel Mgmt., Anthem Blue Cross & Blue Shield,
Midwest Region: Patient Safety Initiative, http://www.opm.gov/insure/archive/05/safety/R5.asp (last
visited Feb. 20, 2010) (explaining the point-of-sale screening process); 23andMe, Inc., Warfarin
(Coumadin) Sensitivity-Genetic Testing, https://www.23andme.com/health/Warfarin-Coumadin-
Sensitivity/ (last visited Jan. 11, 2010) (discussing the impact of certain genotypes on warfarin
metabolism and the potential adverse reaction if not properly administered).
43. See Jane E. Henney, Comm'r, U.S. Food & Drugs Admin., Remarks at the Conference of the
National Task Force on CME Provider/Industry Collaboration: FDA Perspective on Product Promotion
Issues (Sep. 24, 1999), http://www.fda.gov/NewsEvents/Speeches/ucm054534.htm (commenting on the
increased relationship between the FDA and the pharmacy profession "to better coordinate enforcement
efforts" and "to warn consumers about dangerous [sales] practices").
44. David B. Brushwood, The Professional Capabilities and Legal Responsibilities of Pharmacists:
Should "Can " Imply "Ought"?, 44 DRAKE L. REV. 439, 456 (1996).
45. Durham-Humphrey Drug Prescriptions Act, Pub. L. No. 82-215, 65 Stat. 648 (1951) (codified
as amended at 21 U.S.C. § 353(b) (2006)); Matthew J. Seamon, Plan Bfor the FDA: A Need for a Third
Class of Drug Regulation in the United States Involving a "Pharmacist-Only" Class of Drugs, 12 WM.
& MARY J. WOMEN & L. 521, 539 & n. 156 (2006).
46. Seamon, supra note 45, at 539-40.
47. William L. Allen & David B. Brushwood, Pharmaceutically Assisted Death and the
Pharmacist's Right of Conscience, 5 J. PHARMACY & L. 1, 2 (1995).
48. See, e.g., Steven W. Huang, The Omnibus Reconciliation Act of 1990: Redefining Pharmacists'
Legal Responsibilities, 24 AM. J.L. & MED. 417, 433 (1998) (noting the redefining of the pharmacists'
duties under both common law and statutory obligations).
49. Omnibus Budget Reconciliation Act of 1990, Pub. L. No. 101-508, 104 Stat. 1388.
50. Huang, supra note 48, at 433-34.
51. Id. at 434.
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their medications and check for drug-therapy problems, contraindications, and
similar concerns. 2
At approximately the same time, many of the profession's leaders began
promoting a model known as "pharmaceutical care, 53 a "patient-centered,
outcomes-oriented, pharmacy practice" in which "pharmacists help assess
therapeutic needs, prevent adverse drug reactions, develop patient-specific therapy,
manage chronic disease, and monitor follow-up care." 54 The pharmaceutical care
ideal envisions formal professional collaboration agreements with physicians
55
where both physicians and pharmacists are accountable for drug therapy outcomes,
and pharmacists may even serve in a consultant capacity to the physician.
5 6
Most pharmacists remain primarily distributors of products rather than
providers of services,57 and therefore, their legal relationships with physicians and
customers have been very different.58 The longstanding common law rule was that
a pharmacist could not be held liable for accurately filling a prescription apparently
valid on its face. 59 The basis for the rule was the physician-patient relationship;
60
courts took the view that a pharmacist interfered with a confidential relationship if
she warned a customer of potential contraindications or refused to fill a
52. Id.
53. Jannet M. Carmichael & Janice A. Cichowlas, The Changing Role of Pharmacy Practice-A
Clinical Perspective, 10 ANNALS HEALTH L. 179, 180 (2001).
54. Johanna L. Keely, Pharmacist Scope of Practice, 136 ANNALS INTERNAL MED. 79, 80 (2002).
55. Carmichael & Cichowlas, supra note 53, at 180, 184, 188.
56. See David B. Brushwood, From Confrontation to Collaboration: Collegial Accountability and
the Expanding Role of Pharmacists in the Management of Chronic Pain, 29 J.L. MED. & ETHICS 69, 78-
80 (2001) (discussing accountability in collaborative drug therapy management programs, including the
pharmacists' responsibility as a consultant who assists an attending physician).
57. David S. Walker & Stephen G. Hoag, Foreword, 44 DRAKE L. REv., at i, ii (1996).
58. See, e.g., Eldridge v. Eli Lilly & Co., 485 N.E.2d 551, 554-55 (I11. Ct. App. 1985) (stating that
a pharmacist has no duty to warn a physician that the prescription is for an excessive quantity as this
would cause a pharmacist to intrude upon the physician-patient relationship); David B. Brushwood, The
Pharmacist's Duty to Warn: Toward a Knowledge-Based Model of Professional Responsibility, 40
DRAKE L. REv. 1, 11-14 (1991). Brushwood summarizes one perspective that a pharmacist is either
unnecessary or downright harmful in the role of providing information or disclosing risks to patients by
identifying several commonly held judicial presumptions, namely, that physicians are themselves doing
a good job providing sufficient information to patients about the drugs they prescribe, that pharmacists
who provide risk disclosure are second-guessing the physician, and that patients should not modify their
drug use as a result of information they receive from someone other than their doctor. Brushwood,
supra, at 12-13.
59. E.g., Adkins v. Mong, 425 N.W.2d 151, 152 (Mich. Ct. App. 1988) ("[A] pharmacists will not
be held liable for correctly filling a prescription issued by a licensed physician."); Brushwood, supra
note 44, at 444 ("Until recently, courts have nearly unanimously rejected pharmacist liability for
problems caused by drugs the pharmacist correctly dispensed.").
60. E.g., Pysz v. Henry's Drug Store, 457 So.2d 561, 562 (Fla. Dist. Ct. App. 1984) (holding that
even when the pharmacist has greater knowledge of a given drug, the physician "has the duty to know
the drug that he is prescribing and to properly monitor the patient").
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prescription.6' Other courts justified not imposing a duty to warn on pharmacists
with the related argument that pharmacists would not know a customer's full
medical history.62 Judicial attitudes changed at the same time pharmacy education
became more clinically oriented and sophisticated,63  pharmaceutical care
aspirations emerged,64 and day-to-day practice became "computerized., 65 For
example, in a case where a pharmacist filled two prescriptions for a customer
written by the same doctor on two different days, 66 a Tennessee appellate court
relied on state pharmacy regulations implying notions of pharmaceutical care to
hold that, for the purposes of summary judgment, the pharmacist may have a duty
to warn the customer of the danger of a potentially serious interaction.
67
Other states relied on notions of pharmaceutical care and the computerization
of the profession when defining pharmacists' duties.68 When overturning a
summary judgment in favor of a pharmacist for failing to warn a customer when
the doctor had prescribed too large a dose of medication,69 the Missouri Court of
Appeals noted that state pharmacy regulations defined a pharmacist's professional
role as similar to the pharmaceutical care model:
61. E.g., McKee v. Am. Home Prods., Corp., 782 P.2d 1045, 1051 (Wash. 1989) ("Requiring the
pharmacist to warn of potential risks associated with a drug would interject the pharmacist into the
physician-patient relationship and interfere with ongoing treatment."); Brushwood, supra note 58, at 12
("Courts also presume that a pharmacist who provides information about risk to a patient is 'second-
guessing' the physician.").
62. E.g., Leesley v. West, 518 N.E.2d 758, 762 (Ill. App. Ct. 1988) ("The foreseeability of injury to
an individual consumer in the absence of any particular warning also varies greatly depending on the
medical history and condition of the individual-facts [that] we cannot reasonably expect the pharmacist
to know.").
63. See Cacciatore, supra note 20, at 104 (describing current requirements of pharmacy students,
including learning how to communicate drug information to patients and health care providers as well as
clinical rotations); e.g., Lasley v. Shrake's Country Club Pharmacy, Inc., 880 P.2d 1129, 1130-34 (Ariz.
Ct. App. 1994). The Lasley court rejected the approach of courts in other jurisdictions that pharmacists
have no duty to warn of possible adverse side effects or excessive doses. Id. at 1133-34. Instead, the
court found that the defendant pharmacy owed a duty to the customer because pharmacists are
professionals, and that it was up to the jury to determine whether the pharmacy's conduct breached the
standard of care that the duty required. Id. at 1130.
64. See supra notes 53-56 and accompanying text.
65. Cacciatore, supra note 20, at 112-13 (noting that in one case, Walker v. Jack Eckert Corp., 434
S.E.2d 63 (Ga. Ct. App. 1993), the court held that pharmacists had a duty to warn after the effective date
of the OBRA 90 regulations, because patient records would be available).
66. Dooley v. Everett, 805 S.W.2d 380, 382 (Tenn. Ct. App. 1990).
67. Id. at 386.
68. See Morgan v. Wal-Mart Stores, Inc., 30 S.W.3d 455, 466 (Tex. App. 2000) (noting that courts
that have found an affirmative duty to warn for pharmacists on the basis of the presence of additional
factors, such as known contraindications); Hooks SuperX, Inc. v. McLaughlin, 642 N.E.2d 514, 519
(Ind. 1994) (holding that the existence of a computerized system at the defendant pharmacy gave the
pharmacist "easy access" to the customer's prescription history, a fact conducive to the finding of a duty
to warn).
69. Homer v. Spalitto, I S.W.3d 519, 521-22, 524 (Mo. Ct. App. 1999).
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Pharmacists have the training and skills to recognize when a
prescription dose is outside a normal range. They are in the best position
to contact the prescribing physician, to alert the physician about the
[excessive] dose and any contraindications relating to other
prescriptions the customer may be taking as identified by the pharmacy
records, and to verify that the physician intended such a dose for a
particular patient. We do not perceive that this type of risk management
unduly interferes with the physician-patient relationship.7 °
The Indiana Supreme Court also held during the 1990s that a pharmacist who
filled prescriptions more quickly than indicated for a safe use drug had a duty to
refrain from dispensing the drug further.71 That court even stated: "The relationship
between pharmacist and customer is a direct one based upon contract and is
independent of the relationship between physician and patient.,
72
A foundational case implying how the FDA might tie regulatory compliance
to risk management strategies was the Illinois Supreme Court's 2002 decision in
Happel v. Wal-Mart Stores, Inc.73 The issue on appeal was "whether a pharmacy
has a duty to warn about a known drug contraindication where the pharmacy is
aware of a customer's drug allergies and knows that the medication prescribed by
the customer's physician is contraindicated for a person with those allergies. 74 The
Wal-Mart store where Heidi Happel took a prescription for Toradol kept a profile
of each customer's allergies and prescription history in its computer system. 75 The
purpose of maintaining these records was to warn of contraindications.76 The
computer system would alert the pharmacist if a drug was contraindicated and then
the pharmacist was supposed to telephone the physician to determine whether she
should override the system and dispense the medication.77 The pharmacist on duty
the day Happel presented her prescription had no recollection of making the
necessary call.78 The court held that when the pharmacist asked customers about
their allergies to various medications, Wal-Mart was "engendering reliance in the
customer that the pharmacy will ... ensure that the customer does not receive a
drug to which the customer is allergic" and therefore assuming a duty to wam.79
70. Id. at 523.
71. Hooks SuperX, Inc., 642 N.E.2d at 516, 519.
72. Id. at 517.
73. 766 N.E.2d 1118 (111. 2002).
74. Id. at 1120.
75. Id. at 1121.
76. Id.
77. Id.
78. Id.
79. Id. at 1124-25.
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As Happel suggests, even regulatory reform is second to computerization in
changing the legal landscape of pharmacy practice.80 Before every pharmacy had
computers to maintain patient records and identify contraindications, fulfilling a
duty to warn or to refuse to dispense based on a customer's prescription history was
difficult. 8' By 2002, however, things had changed: in Happel, the Wal-Mart
computer system would have flashed "drug interaction" across the screen where the
pharmacist could not have missed it.82 Lawyer and Doctor of Pharmacy, Gary G.
Cacciatore explains: "Today, pharmacists rely on computers to provide
comprehensive pharmaceutical care to patients ... [including:] screening for drug-
drug interactions, screening for drug-allergy interactions, screening for duplicate
therapy, printing patient education materials, and maintaining patient profiles. 83
Legal and societal expectations for the pharmacy profession have changed enough
for the FDA and physicians to partner with pharmacists to distribute drugs
appropriate for a particular customer's genotype.84
Il. FDA REGULATORY AUTHORITY AND PHARMACOGENOMICS
The FDA has two frequently competing missions where innovative drugs are
concerned: to ensure that drugs are "safe and effective, 85 and also to "advanc[e]
the public health by helping to speed innovations that make medicines and foods
more effective, safer, and more affordable ...,86 These two missions translate into
conservative procedures for approving new investigational and new drug
80. See Sokol & Molzen, supra note 15, at 463 (stating that some accreditation agencies and state
governments are advocating or mandating technological solutions as a means of curbing medical
prescription errors).
81. See, e.g., Hand v. Krakowski, 453 N.Y.S.2d 121, 122-23 (N.Y. App. Div. 1982) (holding that
where a patient record identified her as an alcoholic, and a pharmacist dispensed a large amount of a
psychotropic drug that is contraindicated for alcoholics, the pharmacist could be held liable for
dispensing); Cacciatore, supra note 20, at 107 ("[T]he duty to wam recognized in Hand is not a general
duty to warn. It has instead been limited to the unique fact situation where a pharmacist has special
knowledge about the patient that created a substantial risk of serious harm.").
82. 766N.E.2d at 1121.
83. Cacciatore, supra note 20, at 113.
84. See Riff v. Morgan Pharmacy, 508 A.2d 1247, 1251 (Pa. Super. Ct. 1986) (stating that because
pharmacology is a regulated profession requiring, among other things, a specialized, accredited degree,
licensing, and satisfactory performance on an exam, a pharmacist's role is not only to unthinkingly
dispense medication, but also to exercise an adequate standard of care in dispensing medicine to a
customer); Justina A. Molzon, The FDA's Perspective on the Future of Pharmacy, 44 DRAKE L. REV.
463, 464 (1996) (stating the FDA's position that all health-related professionals, including both
pharmacists and physicians, need to work together to take advantage of technological advances so as to
target information to individual patients).
85. See U.S. Food & Drug Admin., What We Do, http://www.fda.gov/opaconi/morechoices/
mission.html (last visited Feb. 20, 2010) ("The FDA is responsible for protecting the public health by
assuring the safety, efficacy, and security of... drugs ....
86. Id.
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applications8 7 and encouragement for voluntary innovation in research and
88development of new drugs, devices, and biologics. As a result, human genome
research has produced only a few new drug applications and the industry has not
taken advantage of pharmacogenomics, despite FDA cajoling.89 The challenge now
is to find ways to do so.
90
The FDA's rigorous testing requirements create a practical problem for
sponsors of drugs that may require genetic testing to confirm safety: money.9' To
start the process of eventual FDA approval, a sponsor must obtain an
"investigational new drug" designation that allows it to conduct the required three
phases of clinical tests on human beings. 92 The first phase requires only a small
number of participants-twenty to eighty-for the purpose of obtaining early
evidence of safety and effectiveness.93 Phase II and III studies require hundreds and
thousands of participants.94
Identifying biomarkers that will influence the safety or effectiveness of the
drug for various groups can both contribute to as well as reduce these costs.95 As
early as Phase I studies, the FDA expects the sponsor to look for evidence of how
subjects metabolize the drug, other biologic phenomena, and disease processes.96
Phase I studies are the first opportunity a sponsor may have to collect data about
87. See generally Abigail Alliance for Better Access to Developmental Drugs v. von Eschenbach,
495 F.3d 695, 697 (D.C. Cir. 2007) (upholding FDA decision not to make experimental drugs available
to persons with terminal illnesses).
88. CTR. FOR DRUG EVALUATION & RESEARCH ET AL., U.S. DEP'T OF HEALTH & HUMAN SERVS.,
GUIDANCE FOR INDUSTRY: PHARMACOGENOMICS DATA SUBMISSIONS 7 (2005), available at
http://ww-w.fda.gov/downloads/Drugs/GuidanceCompliantceRegulatoryInformation/Guidances/ucmO798
49.pdf [hereinafter PHARMACOGENETICS DATA SUBMISSIONS].
89. See U.S. FOOD & DRUG ADMIN., U.S. DEP'T OF HEALTH & HUMAN SERVS., INNOVATION OR
STAGNATION: CHALLENGE AND OPPORTUNITY ON THE CRITICAL PATH TO NEW MEDICAL PRODUCTS, at
i-iv (2004), available at http://www.fda.gov/downloads/ScienceResearch/SpecialTopics/CriticaPath
Initiative/CriticalPathOpportunitiesReports/ucm 11341 l.pdf (noting a reduction in recent developments
in the areas of drugs, devices, and biologics, summarizing various reasons for the slow technological
advance and describing the FDA initiatives to stimulate development in these areas).
90. Id. at 5.
91. See David J. Wu, A Pharmacogenomics Standard for FDA Drug Approval: Arbitrary and
Capricious or Safe and Effective?, 23 BIOTECHNOLOGY L. REP. 733, 737-39, 743-44 (2004) (discussing
the FDA drug approval requirements and the economic challenges for the drug developer).
92. 21 C.F.R. § 312.20(a) (2009).
93. Id. § 312.21(a)(1).
94. Id. § 312.21(bHc).
95. STEVE OLSON ET AL., INST. OF MED., ACCELERATING THE DEVELOPMENT OF BIOMARKERS FOR
DRUG SAFETY: WORKSHOP SUMMARY 1 (2009); see Stephen A. Williams et al., A Cost-Effectiveness
Approach to the Qualification and Acceptance of Biomarkers, 5 NATURE REVIEWS DRUG DISCOVERY
897, 898 box 1, 899 (2006) (explaining that there can be situations where the costs of false results
obtained by using biomarkers are greater than the value of the benefits obtained from the true results,
and because it is hard to predict the efficiency of biomarkers' predictions ahead of time, some markers
are not "discovered" as inefficient until after they have returned false results).
96. § 312.21(a)(2).
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genetic variation in humans,97 but unfortunately for the sponsor whose proposed
drug may die on the vine based on this information, it may already have invested
considerable resources to develop the drug with animal and other studies.98 Phase II
and III tests are even more onerous and expensive and have similar requirements.99
Therefore, genetic testing even before evidence of variable outcomes emerges can
control budgets.
00
On the other hand, the cost concern can also be a disincentive to testing drugs
with genetically variable outcomes.' 0' The interface of costs and ethics is an
example.' 0 2 The "common rule" applies to investigational new drug studies, 10 3 and
therefore, an Institutional Review Board may not approve a study where the risks to
some participants are not reasonable in light of the benefits. 10 4 Genetic screening
can remove participants at risk from a study and target participants similar to those
who will ultimately use the drug, 10 5 producing data to form a basis for ultimate
FDA approval for limited population groups and indications.'0 6 The FDA has even
97. E.g., id. § 312.23(a)(3) (explaining that animal and other studies must be included in an
investigational new drug application).
98. See U.S. FOOD & DRUG ADMIN., supra note 89, at 8 (explaining that a new medical compound
entering the Phase I study process has been subject to ten years of preclinical testing but has only an
eight percent chance of ultimate FDA approval, and that a ten percent improvement in predicting
failures prior to clinical trials could save $100 million per drug); Lawrence J. Lesko & Janet Woodcock,
Translation of Pharmacogenomics and Pharmacogenetics: A Regulatory Perspective, 4 NATURE
REVIEWS DRUG DISCOVERY 763, 764 (2004) (stating that developing a new drug is a massive
investment that can cost upwards of $800 million and can take an average of eight to ten years).
99. See § 312.21(b)-(c) (detailing the additional requirements for Phase I1 and Ill trials); U.S. FOOD
& DRUG ADMIN., supra note 89, at 3-4 (estimating cost of bringing a new drug to market to be as high
as $0.8 to $1.7 billion as compared to the amount needed to get to Phase I studies); Lesko & Woodcock,
supra note 98, at 764 (noting the increasing cost and complexity of clinical trials, particularly in Phase
III).
100. PETER TOLLMAN ET AL., BOSTON CONSULTING GROUP, A REVOLUTION IN R&D: HOW
GENOMICS AND GENETICS ARE TRANSFORMING THE BIOPHARMACEUTICAL INDUSTRY 26-27 (2001),
available at http://209.83.147.85/impact-expertise/publications/files/eng-genomicsgenetics-rep-
11 _0l .pdf.
101. Richard Weinshilboum & Liewei Wang, Pharmacogenomics: Bench to Bedside, 3 NATURE
REVIEWS DRUG DISCOVERY 739, 745, 747 (2004).
102. See Paolo Preziosi, Science, Pharmacoeconomics and Ethics in Drug R&D: A Sustainable
Future Scenario?, 3 NATURE REVIEWS DRUG DISCOVERY 521, 524-26 (2004) (discussing the ethical
and financial concerns associated with the drug development process).
103. 45 C.F.R. § 46.101 (2009); see also Abney v. Amgen, Inc., No. 5:05-CV-254-JMH, 2005 U.S.
Dist. LEXIS 14258, at *6 (E.D. Ky. July 8, 2005) (stating that 45 C.F.R. § 46.101 is "otherwise known
as the Common Rule").
104. 21 C.F.R. § 56.11 l(a)(2) (2009).
105. PETER TOLLMAN ET AL., supra note 100, at 33-34.
106. See 21 C.F.R. § 314.50(d)(5)(vi)(a) (requiring information about drug safety in certain
populations, such as gender, age, and racial subgroups); Wu, supra note 91, at 738 (explaining that
contemporary technology allows for genetic screening to remove patients at high risk of complications
from clinical trials, rendering invalid the arguments that drug companies have used in the past to attempt
to avoid FDA testing requirements). The FDA is encouraging studies with more diverse sets of
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urged sponsors to submit pharmagenomic data voluntarily by promising it will not
be used against the sponsor. 10 7 While the clinical trials may be cheaper, however,
the sponsor may have difficulty recouping its pre-marketing investment because of
the drug's limited utility.'
0 8
Studies targeted at either those with or without the relevant biomarker will not
defeat approval.'0 9 To obtain approval for limited populations or indications, the
sponsor must explain in the new drug application that follows the three phases of
studies how the drug may or may not be both safe" 0 and effective."' The sponsor
and the FDA must then agree on means to protect these groups at risk."
l2
Depending on the nature and severity of the risks, these safeguards may include
information on the label such as lists of contraindications, warnings, and even
"black box" warnings;"13 sending Dear Doctor letters explaining the risks of off-
label use; 1 14 informing pharmacists about a drug's appropriate indications and
dosage;" 5 or implementing risk management strategies.''
6
Getting such a drug approved is not a simple task, but the paucity of reliable,
valid genetic tests makes marketing it even more difficult.' ' 7 The FDA treats
genetic tests as devices" 18 and has approved few, though the number and impact on
participants due to physicians' widespread "off-label" prescribing of drugs to those for whom the drugs
were not tested. Noah, supra note 16, at 13-14.
107. CTR. FOR DRUG EVALUATION & RESEARCH ET AL., supra note 88, at 14.
108. Kelton, supra note 14, at 6-7 (explaining that pharmaceutical companies focus on
"blockbuster" drugs that generate more than $I billion as opposed to personalized drugs).
109. See, e.g., § 314.50(d)(5)(v). "Effectiveness data from other subgroups of the population of
patients treated [shall be presented], when appropriate." Id. The submission of this information is not
required for approval, and therefore a drug can be approved independent of a biomarker study.
110. See id. § 314.50(d)(5)(vi)(a) ("The applicant shall submit an integrated summary of all
available information about the safety of the drug .... ").
111. See id. § 314.50(d)(5)(v) ("The applicant shall submit ... [a]n integrated summary of the data
demonstrating substantial evidence of effectiveness for the claimed indications."). The regulations refer,
for example, to persons with renal failure, id., but biomarkers more generally are analogous.
112. Cf Michael Baram, Making Clinical Trials Safer for Human Subjects, 27 AM. J.L. & MED. 253,
274-75 (2001) (discussing the negotiating process between the sponsor and the FDA to determine what
precautionary actions should be implemented to adequately ensure the safety of test participants); Steven
E. Nissen, Editor's Commentary, A Much-Anticipated FDA Reform Bill Is Signed into Law: Progress
and Compromise, 10 CURRENT CARDIOLOGY REP. 1, 1 (2008) (commenting on the necessary
negotiation process between the pharmaceutical industry and the FDA in order to successfully relabel
drugs).
113. § 201.57(a)(4), (9), (10); Mandry, supra note 7, at 532.
114. § 200.5; Rothstein, supra note 14, at 119-20.
115. § 200.7.
116. See supra notes 7-17 and accompanying text.
117. See generally Gail H. Javitt & Kathy Hudson, The Right Prescription for Personalized Genetic
Medicine, 4 PERSONALIZED MED. 115, 115-16 (2007) (explaining that there are very few FDA-
approved test kits because laboratories can develop and market their own non-FDA approved genetic
test kit, which results in fewer reliable kits).
118. 21 U.S.C. § 321(h) (2006). The definition of "device" pursuant to the Food, Drug, and
Cosmetic Act is:
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genetic testing's availability is increasing.' l 9 Most genetic tests are either kits 12 0 or
a laboratory's in-house manufactured test known as a home brew.'21 The FDA does
regulate kits, 122 but home brews are mostly unregulated. 123 The one home brew the
FDA does regulate is the In Vitro Diagnostic Multivariate Index Assay
(JVDMIA), 124 but the agency justifies its disputed authority with the mere thin reed
of a draft guidance. 25 The FDA does require that advertising and promotional
materials for home brews state that their "[a]nalytic and performance characteristics
are not established" and make no other statements about the test's performance,
12 1
[A]n instrument, apparatus, implement, machine, contrivance, implant, in vitro reagent, or
other similar or related article, including any component, part, or accessory, which is . . .
intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation,
treatment, or prevention of disease, in man or other animals, or... which does not achieve its
primary intended purposes through chemical action within or on the body of man or other
animals and which is not dependent upon being metabolized for the achievement of its
primary intended purposes.
Id. For an explanation of why a combination of the statute and the accompanying regulation may not
authorize the FDA to regulate "devices" such as the In Vitro Diagnostic Multivariate Index Assay, see
supra note 84.
119. See Javitt & Hudson, supra note 117, at 116 (noting that while the FDA has approved few test
kits in the past, it has recently announced that it will begin to regulate a small subset of laboratory
developed tests).
120. Gregorio M. Garcia, The FDA and Regulation of Genetic Tests: Building Confidence and
Promoting Safety, 48 JURMETRICS 217, 218 (2008). Kits are sold and used outside a developing
laboratory or facility. Id.
121. Home brews are used in-house or in the developing laboratory. Id.
122. See, e.g., 21 C.F.R. § 809.30 (2009) (regulating the sale of Analyte Specific Reagents, a test
developed for in-house and laboratory use).
123. 62 Fed. Reg. 62,249, 62,249 (Nov. 21, 1997) (explaining that, while the home tests are under
FDA jurisdiction, the agency declines to classify them as class II or III medical devices for regulation);
61 Fed. Reg. 10,484, 10,484 (Mar. 14, 1996) (stating that "home brew" tests have not been actively
regulated by the FDA); see Petition from Sean A. Johnston, Senior Vice President & General Counsel,
Genentech, to Div. of Dockets Mgmt., U.S. Food & Drug Admin. (Dec. 5, 2008), available at
http://www.regulations.gov/search/Regs/home.html#documentDetail?R=09000064807d4a7e (requesting
that the FDA increase regulation of in vitro diagnostic tests).
124. See 21 U.S.C. § 360(e), (k) (2006) (outlining the requirements for class 11 and III medical
devices); CTR. FOR DEVICES & RADIOLOGICAL HEALTH ET AL., U.S. DEP'T OF HEALTH & HUMAN
SERVS., DRAFT GUIDANCE FOR INDUSTRY, CLINICAL LABORATORIES, AND FDA STAFF: IN VITRO
DIAGNOSTIC MULTIVARIATE INDEX ARRAYS 3, 7-8 (2007) (discussing IVDMIAs and the FDA
requirement of pre- and post-market approval for those that fit into class II and III); In Vitro Diagnostic
Multivariate Index Assays; Notice of Availability, 72 Fed. Reg. 41,081, 41,081-82 (July 26, 2007)
(noting that the revised draft guidance identifies IVDMIAs as a discrete category that must meet pre-
and post-market device requirements); Jeffrey S. Ross et al., Commercialized Multigene Predictors of
Clinical Outcome for Breast Cancer, 13 ONCOLOGIST 477, 485 (2008) (noting one IVDMIA that has
received clearance from the FDA).
125. CTR. FOR DEVICES & RADIOLOGICAL HEALTH ET AL., supra note 124, at 4; Garcia, supra note
120, at 221. Mr. Garcia is not convinced that the FDA has authority under the Food, Drug, and Cosmetic
Act to regulate IVDMAs because the FDA has chosen to regulate the reagents used in the test devices
only if they have moved in interstate commerce and not those created by the lab in which they are used.
/d. at 227.
126. 21 C.F.R. § 809.30(d)(2), (4).
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because they are "not clinically validated."'12 7 The regulations also require that the
laboratory put a notification on the test result that the test is not cleared or approved
by the FDA. 128 Home brews are hardly the lantern on which to hang the
pharmacogenomics industry.
Approved tests do provide hope that pharmacogenomics will ultimately guide
physicians to appropriate drug choices for their patients. 29 Studies concluded in
2004 showed that clinical outcomes from the use of warfarin, the active ingredient
in the anti-coagulant Coumadin, were associated with CYP2C9 gene variant.'
30
Patients with different CYP2C9 alleles had different risks of anticoagulation, which
in some patients corresponded to life-threatening bleeding.' 3 ' The FDA recently
approved a test for polymorphisms in two enzymes, CYP2C9 and VKORC 1, which
will help determine proper dosing for patients using Coumadin.13 2 These
developments could have a dramatic effect: almost ten percent of the population
has the gene mutation that affects the metabolism of warfarin, 133 and only insulin is
more often cited than Coumadin as the culprit for emergency room adverse drug
events. 1
34
Another example is the drug Herceptin, used to treat breast cancer and the
first drug approved based on pharmacogenomics. 135 The drug is indicated only if a
woman is one of the thirty percent of those with breast cancer who also has an
over-expression of a protein called human epidermal growth factor receptor 2
(HER2) on breast cells. 136 HER2 can make those cells multiply uncontrollably, so
that women with the condition do not respond well to other breast cancer
therapies. 37 Herceptin, however, can increase these women's survival rate, and
genetic tests now exist to determine if Herceptin can help.1
38
127. Garcia, supra note 120, at 221 (quoting documents from Centers for Medicare and Medicaid
Services).
128. 21 C.F.R. § 809.30(e).
129. See Xie & Frueh, supra note 17, at 332.
130. E.g., M. Wadelius et al., Warfarin Sensitivity Related to CYP2C9, CYP3AS, ABCB1 (MDR1)
and Other Factors, 4 PHARMACOGENOMICS J. 40, 41 (2004); Bristol-Myers Squibb, Medication Guide:
Coumadin (COU-ma-din) Tablets (Warfarin Sodium Tablets, USP) Crystalline (2009), available at
http://packageinserts.bms.com/pi/pi-coumadin.pdf.
131. Wadelius et al., supra note 130, at 41; Bristol-Myers Squibb, supra note 130 (including
information of risk to carriers of the CYP2C9 alleles).
132. Shashi Amur et al., Integration and Use of Biomarkers in Drug Development, Regulation and
Clinical Practice: A US Regulatory Perspective, 2 BIOMARKERS MED. 305, 308 (2008).
133. Marchant, supra note 20, at 14.
134. Press Release, U.S. Food & Drug Admin., FDA Approves Updated Warfarin (Coumadin)
Prescribing Information: New Genetic Information May Help Providers Improve Initial Dosing
Estimates of the Anticoagulant for Individual Patients (Aug. 16, 2007),
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm I08967.htm.
135. Kelton, supra note 14, at 5.
136. Id.
137. Id.
138. Id.
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Therefore, in the short term, FDA regulation does limit health care
professionals' ability to take full advantage of pharmacogenomics, but no more
than do industry leaders not developing genetically-based drugs and genetic test
that provide clinically valid results. Nevertheless, society would not benefit from
pharmacogenomics' full potential even if science could identify all safe and
effective drugs based on a patient's genotype and technology could produce as
many reliable and valid genetic tests as needed. 139 Revolutionary change is never
possible without "boots on the ground."
III. PHARMACISTS: PHARMACOGENOMICS' "BOOTS ON THE GROUND"
Relying on physicians alone will not ensure that patients receive genetically
compatible drugs and dosing instructions. They need a backstop: 140 in just one
survey published in 1997, 46% of the 461 nursing home pharmacists reported that
physicians regularly prescribed drugs not indicated for the elderly; that were
inconsistent with labeling; and were not given according to prescriptions because of
poor recordkeeping and communication with pharmacists and patients. 14 1 Further,
the FDA has no control over physicians' use of approved drugs, because the states,
not the federal government, regulate the practice of medicine. 42 Physicians are also
familiar with "off-label" prescribing: prescribing drugs for purposes and in doses
not listed on the FDA approved package insert; 143 personalized medicine, the
139. See Brushwood, supra note 44, at 459-60 (noting that achieving the full potential of
pharmaceutical care is a complex interaction between physicians, patients, and pharmacists); infra Part
III (describing how pharmacists are an integral part of reaching the full potential of pharmacogenomics).
140. See, e.g., Bob Neiner, Note, A New Cure for Contraindication: Illinois Supreme Court
Prescribes a Duty to Warn on Pharmacists: Happel v. Wal-Mart Stores, Inc., 766 N.E.2d 1118 (Ill.
2002), 28 S. ILL. U. L.J. 483, 490 (2004) (noting that the physician prescribed Toradol without knowing
that the drug was contraindicated for an aspirin user).
141. Huang, supra note 48, at 419; see also Sokol & Molzen, supra note 15, at 462 (explaining that a
physician's failure to adjust medications for patients with disease or physiological factors that alter drug
action is a common form of medication error). Physicians are hardly the only culprits, however. For
professionals held to a strict liability standard when its errors injure customers, it is disconcerting that
pharmacists make errors when filling three to five percent of prescriptions. Eric M. Grasha, Note,
Discovering Pharmacy Error: Must Reporting, Identifying, and Analyzing Pharmacy Dispensing Errors
Create Liability for Pharmacists?, 63 OHIO ST. L.J. 1419, 1425 (2002).
142. The Sixth Circuit explains:
Absent state regulation, once a drug has been approved by the FDA, doctors may presecribe
it for indications and in dosages other than those expressly approved by the FDA. This is a
widely employed practice known as "off-label" use. Off-label use does not violate federal
law or FDA regulations because the FDA regulates the marketing and distribution of drugs in
the United States, not the practice of medicine, which is the exclusive realm of individual
states.
Planned Parenthood of Cincinnati Region v. Strickland, 531 F.3d 406, 408 (6th Cir. 2008) (quoting
Planned Parenthood of Cincinnati Region v. Taft, 444 F.3d 502, 505 (6th Cir. 2006)).
143. See Barbara Chevalier, The Constitutionality of the FDA's Age-Based Plan B Regulations: Why
the FDA Made the Wrong Decision, 22 WIS. WOMEN'S L.J. 235, 249 (2007) (explaining that states
retain the power to regulate both prescription and non-prescription drugs).
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practical offspring of pharmacogenomics, is definitionally antithetical to off-label
drug use.
Pharmacists' increased education and professional aspirations imply both
greater knowledge and responsibility to assist physicians in drug therapy choices
and outcomes.144 A regulatory model requiring that pharmacists only fill
prescriptions after receiving evidence that a customer either has a genotype
appropriate for a particular drug or dose is within reach. 45
A. The Model: Conditioning Dispensation on Appropriate
Genetic Test Results
The model for ensuring that patients receive the right drugs in appropriate
doses based on their genotypes requires that pharmacists condition dispensation on
evidence of appropriate genetic test results.1 46 Over the long term, applying such a
model to the ideal of personalized medicine will require sophisticated genetic tests
not yet available at costs that are not yet affordable, 147 widespread dissemination of
pharmacogenomic data, 148 and extensive professional training.' 49 Further, while the
FDA can use its power to impose risk management strategies to require that
manufacturers make sure that only "certified" pharmacists dispense drugs safe only
for certain groups, this power may not extend to drugs efficacious only for certain
groups. 150 Nevertheless, the FDA and the pharmaceutical industry have identified
enough drugs that produce variable outcomes based on genotype and have created
appropriate tests to begin implementing a program involving pharmacists that can
144. Brushwood, supra note 44, at 458-61.
145. See Malinowski, supra note 25 , at 52-53 (commenting that, while individually tailored health
care provided by pharmacists may be decades away, such a model is a glimpse into the foreseeable
future); Gilhooley, supra note 5, at 945-47 (proposing similar use of distribution limits, but applying
them only voluntarily). This model will only be practical, however, if regulators and the pharmaceutical
industry offer products compatible with the limits of pharmacy practice.
146. See Brushwood supra note 44, at 459 (explaining that pharmacists would be in a position to
improve health outcomes for patients by examining patient records, reports, and other information to
recognize indicators of suboptimal outcomes and act on that information).
147. Kelton, supra note 14, at 5-6 (describing the handful of cost-effective tests and the Centers for
Medicare & Medicaid Services' failure to approve and provide oversight of genetic tests); see also
Malinowski, supra note 25, at 52-53 (noting the limitations of"homebrew" tests); Marchant, supra note
20, at 14-16 (noting that insurers may not see the cost-effectiveness of expensive tests).
148. See, e.g., Kelton, supra note 14, at 5 (explaining that package inserts fail to provide information
necessary to guide pharmacogenomic therapy); Wu, supra note 91, at 740-41 (explaining that providing
pharmacogenomic data may have to be modified on many existing drugs).
149. Xie & Frueh, supra note 17, at 332 (noting limited education and training of health care
professionals in using pharmacogenomic data).
150. See 21 U.S.C.A. § 355-1(0(3) (West Supp. 2009) (referring only to "[e]lements to assure safe
use" (emphasis added)). This authorization appears on its face to apply only to drugs unsafe in certain
circumstances. Efficacy is only an issue to the extent that the "benefits of the drug outweigh the risks of
the drug.. .. '" Id. § 355-1(a)(1).
[VOL. 13:77
FDA AND THE PHARMACY PROFESSION
grow along with the FDA's exercise of its regulatory power and health care
industry's ever more sophisticated knowledge over time. 151
Such a model will only work on the ground if it is easy to use, compatible
with current pharmacy practice, and enforceable via regulatory or judicial means.152
It will require using the kind of computer technology that is already standard in
pharmacies to identify drugs with potential genetically-based contraindications or
dosing limitations. 53 When a customer presents a prescription for such a drug, the
computer software will warn the pharmacist to obtain a genetic test report or
contact the physician for authority to override the warning and dispense the
medication.
54
B. Ease of Use
The model must be easy to use. Not all pharmacists have the specialized
knowledge to identify genetically-based drugs on their own,' 55 and though
professional organizations and personalized medicine advocacy groups are
providing training programs, 56 these may take years to penetrate the entire
profession. 57 Even if a pharmacist is "certified" according to the FDA's risk
management authority,' 58 he may not fill all prescriptions in his pharmacy, 5
9
especially in chains and managed care institutions. 160 In fact, most pharmacists rely
heavily on low-paid pharmacy technicians who have little or no training to
maximize the number of prescriptions their institution can fill.16 1 Therefore, the
151. Cf Xie & Frueh, supra note 17, at 326-32 (describing numerous known drugs with genetically
variable drug responses as well as speculating as to future developments related to personalized
medicine).
152. See infra Part III.B-D.
153. See Neiner, supra note 140, at 491 (describing a computer system that pharmacists currently
use in filling prescriptions).
154. Cf id. (describing a system that displays a warning on the computer screen when a prescription
is contraindicated and requires the pharmacist to override the system to continue filling the prescription).
155. See Sujit S. Sansgiry & Amit S. Kulkami, The Human Genome Project: Assessing Confidence
in Knowledge and Training Requirements for Community Pharmacists, 67 AM. J. PHARMACEUTICAL
EDUC. 291, 295, 299 (2003) (noting that pharmacists had less than fifty percent confidence in their
knowledge of pharmacogenomics).
156. Xie & Frueh, supra note 17, at 332.
157. Ernie Hood, Pharmacogenomics: The Promise of Personalized Medicine, Ill ENVTL. HEALTH
PERSP. A580, A582 (2003).
158. See 21 U.S.C.A. § 355-1(f)(3)(A)-(B) (West Supp. 2009) (requiring pharmacists to become
"specially certified" in order "to assure safe use").
159. See Huang, supra note 48, at 420 (stating that chain drug stores typically hire two or multiple
pharmacists and often employ pharmacy technicians to "allow[] pharmacists to focus on counseling
customers").
160. Id.
161. Ed Sweeney & James T. O'Donnell, The NABP Model Act and Rules Initiative Toward
Pharmacy Technicians, in JAMES T. O'DONNELL, DRUG INJURY: LIABILITY, ANALYSIS AND
PREVENTION 841, 842-47 (2d ed. 2005).
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model must accommodate overworked professionals who have limited knowledge
or difficulty keeping up with rapidly developing technology.
A computer-based identifier can help bridge the knowledge/attention gap.
162
The same computer system a pharmacy uses to identify contraindications as a result
of allergies or other medications can identify a drug with genetic variations in
safety and efficacy. 163  All such drugs would, by definition, become
"contraindications," such that the computer system would trigger an alert every
time a pharmacist enters a prescription for Coumadin, for example. 164 The
pharmacist could only justify overriding the system and dispensing the drug if the
customer provided a genetic test report showing results consistent with safe or
efficacious use of the drug as prescribed, or the physician confirmed her intention
to prescribe. 165 The evaluation of consistency would be a matter of professional
discretion: one only a pharmacist could perform.1
66
Keeping the model easy will require test facilities to standardize their result
reports or present them in an easily readable format so that pharmacists working in
162. See Sokol & Molzen, supra note 15, at 461 (describing how technology, generally, and
computers, in particular, have the ability to "simplify tasks, reduce errors, and increase efficiency").
163. See Cacciatore, supra note 20, at 112-14 (describing how pharmacists rely heavily on
computers to aid in decision-making such as assisting in screening for drug interactions and
pharmacokinetic consults); loannis S. Vizirianakis, Challenges in Current Drug Delivery from the
Potential Application of Pharmacogenomics and Personalized Medicine in Clinical Practice, I
CURRENT DRUG DELIVERY 73, 78 (2004) (discussing the future of drug selection as evolving in a
computerized environment into a "highly integrated, information-based and computer-aided
pharmacotherapy based decision" that incorporates genetic information, "making drug delivery... more
efficient and safer").
164. See John A. Robertson et al., Pharmacogenetic Challenges for the Health Care System,
HEALTH AFF., July-Aug. 2002, at 155, 160 (noting that in the future it is likely that the need to have a
pharmacogenomic test to "determine whether a patient has a particular drug-response genotype [w]ould
be listed as a contraindication, a warning, or a precaution to prescribing a drug"). This notification
system would be similar not only to current pharmacy procedure, but also to less sophisticated
requirements such as retail stores confirming age when consumers purchase alcoholic beverages or
cigarettes. See, e.g., CTR. FOR SUBSTANCE ABUSE PREVENTION, DRAFT BEST PRACTICES FOR
RESPONSIBLE RETAILING 12 (n.d.), available at http://fcpr.fsu.edu/retail/documents/
BPReportConferenceEdition.pdf (describing checkout register computer programs that prompt the
clerk to scan the customer's identification if tobacco or alcohol are purchased); RESPONSIBLE
RETAILING FORUM, RRFORUM RECOMMENDED PRACTICES FOR OFF-PREMISES ALCOHOL RETAILERS I
(n.d.), available at http://www.rrforum.org/reports/Recommended Practices.Off-PremisesAlcohol
_Licensees_9-09%5B I %5D.pdf (describing register computer programs that prompt cashiers to require
identification and programs that read a customer's identification electronically and calculate age).
165. Cf Happel v. Wal-Mart Stores, Inc., 766 N.E.2d 1118, 1121 (111. 2002) (explaining that if the
pharmacy's computer found a known contraindication a drug interaction warning would flash on the
screen and could only be overridden by entering a special code after consultation with the prescribing
physician).
166. See Sweeney & O'Donnell, supra note 161, at 844 (indicating that only pharmacists, and not
technicians, "are qualified to perform tasks [that] require judgment or discretion[, and] ... to analyze the
potential for drug interactions," and noting that pharmacists have ultimate dispensing authority).
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a fast-paced environment can keep up. 167 The FDA lacks direct authority to impose
reporting criteria on the entire genetic test market because it regulates such a small
portion of available tests, 6 8 but it does have indirect tools at its disposal.1
69
Via its risk mitigation power, the FDA can require that manufacturers
supervise a program allowing "the drug [to] be dispensed to patients [only] with
evidence or other documentation of safe-use conditions, such as laboratory test
results."' 170 This power could extend to the form of the report. 7' Physicians and
hospitals can already use the Amplichip CYP450 Array, which "analyze[s] two
genes.., that encode [two] drug-metabolizing enzymes involved in the metabolism
of... twenty-five percent of all prescription drugs;"' 172 the device is FDA approved
and the agency could also condition ongoing approval on distribution of a
standardized, simple report for a pharmacist. 73 It could do the same with approved
genetic test kits.
Other departments of the federal government have played a vital role in
standardizing reports. 174 The Centers for Medicare & Medicaid Services (CMS) has
authority to ensure the validity of home brews as well as the performance of the
laboratories using them, 175 and while the agency has not exercised that authority,
CMS requires a standardized report form. 76 If Congress gives the FDA authority to
regulate home brew tests, the FDA could then impose a standardized report form
requirement on this large sector of the market. 77 Congress might also achieve
167. See Huang, supra note 48, at 419-20 (describing that pharmacists are overworked due to
intense pressure to fill extreme amounts of prescriptions in very limited time periods, leading to a
compromised degree of care).
168. See Garcia, supra note 120, at 238-39 (noting the uncertainty created by the FDA's lack of
regulation of all genetic tests); supra notes 118-28 and accompanying text.
169. See infra notes 170-78 and accompanying text.
170. 21 U.S.C.A. § 355-1(f)(3)(D) (West Supp. 2009).
171. The statute provides that the risk mitigation power may require drugs only be dispensed if there
is evidence of safe-use conditions. Id. Because this is left as an open-ended category, it is likely that
requiring a standard report form would fall under the statute. Id.
172. Xie & Frueh, supra note 17, at 331 & figi.
173. See, e.g., id. at 331; Wu, supra note 91, at 739-42 (describing approval, labeling, and
withdrawal powers, and how the FDA uses them to obtain concessions from sponsors).
174. E.g., Bruce Patsner, New "Home Brew" Predictive Genetic Tests Present Significant
Regulatory Problems, 9 Hous. J. HEALTH L. & POL'Y 237, 252-53 (2009) (describing the role CMS
plays in ensuring the validity of home brews).
175. See 42 C.F.R. §§ 493.1-2, .5, .15(b)(l) (2009) (stating the conditions that all laboratories must
meet to be certified to perform testing, and limiting laboratories to the performance of only certain tests
of varying complexity); Patsner, supra note 174, at 252.
176. See § 493.1291(a), (c) (requiring a standard test report and indicating what must be included);
Kelton, supra note 14, at 5 (noting the critics' view that CMS "has not provided the necessary
oversight").
177. Cf Garcia, supra note 120, at 224, 232-33 (explaining that the FDA provided guidance for the
regulation of home brew IVDMIAs stating manufacturers must comply with medical device reporting
requirements, and noting the recently proposed legislation granting FDA authority to regulate all home
brew tests). One contentious issue limiting the FDA's ability to regulate, however, would be whether
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many objectives related to genetic testing if it enacted legislation similar to OBRA
90.178
C. Compatibility with Current Pharmacy Practice
Another benefit of this model is its compatibility with current pharmacy
practice. Using computer technology to identify contraindications is increasingly de
rigueur in modem pharmacies. 179 Recently, pharmacists have begun to also control
access to drugs that do not fit into the tidy prescription/over-the-counter
categories. H
°
1. Using Computers to Identify Contraindications
Virtually all pharmacists now use computers to store patient information and
screen for drug interactions. 181 These practices are not only good marketing,182 but
also the common law standard of care in some jurisdictions, 183 as well as arguably a
these home brew laboratories are "practicing medicine." Id. at 235. The federal government might find it
attractive to reimburse laboratories for genetic testing because studies show that doing so would produce
dramatic cost savings from adverse events and unproductive therapy. See, e.g., Andrew McWilliam et
al., Health Care Savings from Personalizing Medicine Using Genetic Testing: The Case of Warfarin 10-
12 (AEI-Brookings Joint Ctr. for Regulatory Studies, Working Paper No. 06-23, 2006) (estimating that,
if the total cost of a test plus labor to take the sample is $350, the use of warfarin alone could result in
anywhere from $70 million to $2.2 billion of net healthcare savings).
178. See Huang, supra note 48, at 433-34 (noting that, as enacted, OBRA 90 only applied to
pharmacists who served Medicaid customers, but a majority of states extended OBRA 90 requirements
to cover all prescriptions not just those reimbursable by Medicaid). Such legislation, which would
require test cost reimbursement by Medicare and Medicaid, would create a strong incentive for all
healthcare providers to use standardized tests to avoid the cost of two report forms. See Cacciatore,
supra note 20, at Il1 (describing that OBRA 90 requirements were only applicable to Medicaid patients,
but most states made them applicable to all patients to prevent the creation of two standards of practice
for pharmacists).
179. See Cacciatore, supra note 20, at 112 ("Computers now play a major role in almost every aspect
of pharmacy practice."); Sokol & Molzen, supra note 15, at 461 (noting the value computers add in the
delivery of safe and effective care); infra Part III.C.I. Among the recommended "safe practices" in
pharmacies is the use of pharmacy computers that will not dispense a drug until key health information
is entered. Sokol & Molzen, supra note 15, at 461.
180. See infra Part III.C.2.
181. Cacciatore, supra note 20, at 112-14.
182. See, e.g., Baker v. Arbor Drugs, Inc., 544 N.W.2d 727, 731 (Mich. Ct. App. 1996) (describing
advertising of a pharmacy computer system designed to detect contraindications).
183. See, e.g., Dooley v. Everett, 805 S.W.2d 380, 383 (Tenn. Ct. App. 1990) (quoting an expert
witness who testified that in a particular Tennessee town, the standard of care required that "pharmacies
maintain a patient profile system," that it "should be reviewed by the pharmacists prior to filling a new
prescription" for contraindications, and that computer technology exists to facilitate that procedure);
Cacciatore, supra note 20, at 114-15 (quoting a prior Revco annual report explaining that Revco
pharmacists, defendants in the Dooley case, should have relied on computers to identify
contraindications).
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requirement of professional codes of ethics. 184 Adding contraindications and
warnings of potential genetic interactions with various drugs is consistent with
what pharmacists already do.' 85
Despite their advantages, computers do sometimes fail to identify
contraindications, 18 6 especially when combined with user error;' 87 therefore, such a
system may be an imperfect backstop for physicians. Many pharmacies may
require a substantial technology upgrade 188 or even additional computer training to
implement this model. 189 Many systems allow overrides with a mere click of a
function key,' 90 and both pharmacists and pharmacy technicians are in the habit of
overriding warnings and contraindications, 191 which would make standardizing
reports irrelevant. The latest systems, however, will improve safety when
184. Am. Pharm. Ass'n, Code of Ethics for Pharmacists, 52 AM. J. HEALTH-SYS. PHARMACY 2131,
2131, at §§ I, V (1995), available at http://www.pharmacist.com/AM/TextTemplate.cfm?Section=
PracticeResources&CONTENTID=2903&TEMPLATE=/CM/HTMLDisplay.cfm.
185. See Huang, supra note 48, at 434-35 (explaining that currently pharmacists must inform
customers of any possible interaction with other drugs and any contraindications).
186. I. Larry Cohen et al., Preventing Medication Errors, in JAMES T. O'DONNELL, DRUG INJURY:
LIABILITY, ANALYSIS AND PREVENTION, supra note 161, at 207, 217; see also Cacciatore, supra note
20, at 116-18 (discussing the responsibility of the pharmacist to ensure that the computer system
"adequately performs those clinical functions that are considered standard in the profession").
187. See Cacciatore, supra note 20, at 117-18 (describing the potential liability for pharmacists
based on user error).
188. See Over-Reliance on Pharmacy Computer Systems May Place Patients at Great Risk, ISMP
MEDICATIONSAFETYALERT! (Inst. for Safe Medication Practices, Horsham, PA), Feb. 10, 1999,
available at http://www.ismp.org/newsletters/acutecare/articles/19990210.asp [hereinafter ISMP
MEDICATION SAFETY ALERT] (stating survey results that indicate that "pharmacy computer systems
need serious improvement"); Salvatore M. Barcia, Managing Change, HEALTH MGMT. TECH., June
2001, at 22, 22 ("Newer [pharmacy computer] systems are unquestionably superior to the [older]
systems they replace.").
189. See Barcia, supra note 188, at 22 (commenting on the fact that newer pharmacy computer
systems that offer more clinical screenings have a higher learning curve); Bill G. Felkey & William
Villaume, Commentary, The Integration of Technology into Pharmacy Education and Practice, INT'L J.
PHARMACY EDUC., Summer 2004, at 1, 1, available at http://www4.samford.edu/schools/pharmacy/ijpe/
104/felkey.pdf (stating that technology generally needs to be incorporated into pharmacy education).
190. See ISMP MEDICATION SAFETY ALERT, supra note 188 (reporting that survey "respondents'
systems require[d] no staff action (such as entering a password) to ensure that the warning was
acknowledged" such that "each warning [could] be bypassed simply by pressing a function key...");
Patient Safety Auth., Results of the PA-PSRS Workgroup on Pharmacy Computer System Safety,
PATIENT SAFETY ADVISORY Su'. 2, May 31, 2007, at 1, 4 ("[A]n average of nearly [nine] in [ten]
systems allow[s] . . . users to override . . . serious warnings. In most cases, the warnings could be
bypassed simply by pressing a function key.").
191. See Inst. for Safe Medication Practices, Heed this Warning! Don't Miss Important Computer
Alerts, PHARMACY TODAY, Feb. 2009, at 52, 52 ("Pharmacists, technicians, or pharmacy intems may
make a habit of bypassing certain alerts during data entry or drug use review especially if they do not
realize the importance of the alert. . . . Frequent false alarms can lead to alert fatigue and
complacency.").
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dispensing all drugs,1 92 and many pharmacists may begin adopting them for that
reason alone.
1 93
Despite excitement about the potential of electronic medical record systems to
provide universally available precision tools for filtering improvidently written
prescriptions,194 they will not offer practical assistance with protecting patients
from genetic contraindications for decades. 95  Electronic medical records
themselves may be commonplace by 2020,196 but many more years may pass
before they become interoperable, so that "dispersed, separately owned, and
separately managed information systems" can "communicate with one another
electronically to share specific bytes of data."'1 97 Different types of health care
providers-doctors, pharmacists, and hospitals, for example-also use different
jargon in their records that blunt their effective use by those in other fields.1 98 Legal
and public policy concerns about privacy with respect to electronic medical
records, especially as to genetic information, 199 may delay their use in
pharmacogenomics even more.200 As a practical matter, routine use of interoperable
electronic medical records will not be standard pharmacy practice in time to help
jumpstart the personalized medicine industry.
192. E.g., Sokol & Molzen, supra note 15, at 461.
193. See, e.g., Don Dietz, Vice President, Pharmacy Healthcare Solutions Inc., Presentation at the
American Society for Automation in Pharmacy Annual Technology & Issues Conference: Emerging
Pharmacy Technology: Rx for Success (Jan. 27, 2006), available at http://www.asapnet.org/
January2006/ASAPJan06_PresentationDietz.ppt (identifying "[c]ontrols and checks to minimize
[prescription] errors" as a "[k]ey component[] of [n]ew [p]harmacy [d]ispensing [s]ystems").
194. See Robert H. Miller & Randall R. Bovbjerg, Efforts to Improve Patient Safety in Large,
Capitated Medical Groups: Description and Conceptual Model, 27 J. HEALTH POL. POL'Y & L. 401,
425 (2002) (describing that almost all physicians interviewed were excited about the use of future
information technology to improve patient safety).
195. See Maren T. Scheuner et al., Are Electronic Health Records Ready for Genomic Medicine?, 11
GENETICS IN MED. 510, 515-17 (2009) (finding that genomics has little impact on electronic records
today but may be viable in the next decade if numerous requirements are meet).
196. Cf Shana Campbell Jones et al., The Interoperable Electronic Health Record: Preserving Its
Promise by Recognizing and Limiting Physician Liability, 63 FOOD & DRUG L.J. 75, 77-78 (2008).
(stating that electronic medical records will reach "[eighty] percent saturation in hospitals by 2016").
197. Rosanna M. Coffey et al., Transforming Mental Health and Substance Abuse Data Systems in
the United States, 59 PSYCHIATRIC SERVS. 1257, 1258 (2008).
198. Jones et al., supra note 196, at 79.
199. 42 U.S.C.A § 1320d-9(a) (West Supp. 2009) (stating that genetic information shall be treated as
health information under the Health Insurance Portability and Accountability Act of 1996, 42 U.S.C.
§ 1320d(4)(B) (2006)); H.R. REP. No. 110-28, pt. 2, at 2 (2007) (describing Congressional findings that
advances in genetics give rise to "potential misuse of genetic information"); Richard Cole, Authentic
Democracy: Endowing Citizens with a Human Right in Their Genetic Information, 33 HOFSTRA L. REV.
1241, 1256-57 (2005) (discussing state and federal legislation regarding protection of personal health
information, including genetic information).
200. See Rosati, supra note 34, at 210-13 (discussing restrictions on the use of genetic testing
information).
[VOL. 13:77
FDA AND THE PHARMACY PROFESSION
2. Increasing Pharmacist Oversight when Dispensing Drugs and Other
Products
Pharmacists no longer sell only drugs classified as either prescription or over-
the-counter drugs. The FDA's risk management programs authorize exceptional
distribution procedures involving pharmacists. 20 1 A majority of pharmacists have
called for a "third class" of drugs they could prescribe themselves.2 °2
Pharmaceutical care implies the existence of enhanced physician-pharmacist
partnerships and collaborative relationships.0 3 Therefore, requiring a genetic test
report prior to dispensing a drug would be within the mainstream of current and
developing pharmacy practice,2°4 even if the physician retained the final say over
how she treated her patient.0 5
In conjunction with physicians, pharmacists increasingly have power to
authorize distribution of numerous well-known drugs.20 6 One such example is
Accutane, a drug administered to treat acne, but can cause birth defects. 0 7
Pharmacists are central to the iPLEDGE risk management program for Accutane.
20 8
First, only registered pharmacists may dispense the drug. 209 Then, because women
must not purchase Accutane later than seven days from the date of the prescription,
pharmacists must confirm that date.2 10 Finally, every month when the woman seeks
to refill her prescription, the pharmacist must contact the iPLEDGE program for
authorization to do so. 2 11
201. 21 U.S.C.A. § 355-1 (West Supp. 2009). See generally Deborah B. Leiderman, Risk
Management of Drug Products and the U.S. Food and Drug Administration: Evolution and Context, 105
DRUG & ALCOHOL DEPENDENCE (SuPP. 1) S9, S10-12 (2009) (summarizing the role of pharmaceutical
risk management in FDA drug policy).
202. Seamon, supra note 45, at 552.
203. See supra notes 53-56 and accompanying text.
204. See supra Part I.
205. Mandry, supra note 7, at 530 (noting that physicians should still exercise discretion in
prescribing because "genetic testing may not enable the physician to determine that the drug is per se
ineffective if the genetic testing shows that the patient is different from other clinical trial subjects").
206. See Brushwood, supra note 56, at 69 (discussing the new responsibilities of the modem
pharmacist). By 2001, twenty-seven states had granted authority to pharmacists to assist physicians in
collaborative drug therapy management and several additional states had proposed similar reforms. Id.
207. See Jeffery D. Evans & Emily W. Evans, Commentary, Review of Eight Restricted-Access
Programs and Potential Implications for Pharmacy, 64 AM. J. HEALTH-SYS. PHARMACY 1302, 1306
(2007) (detailing the expanded role of the pharmacist as part of the iPLEDGE risk management
program, which was aimed at reducing the threat of birth defects that result from use of the drug during
pregnancy).
208. Id.
209. Ami E. Doshi, Comment, The Cost of Clear Skin: Balancing the Social and Safety Costs of
iPLEDGE with the Efficacy ofAccutane (Isotretinoin), 37 SETON HALL L. REV. 625, 644 (2007).
210. Id. at 652. Under the iPLEDGE program, a woman must, among other things, have her
prescription for Accutane filled within seven days of receiving it. Id.
211. ROCHE, ACCUTANE (ISOTRETINOIN CAPSULES) 17, 30 (2010), available at
http://www.gene.com/gene/products/informationaccutane/pdf/pi.pdf.
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The FDA recently approved Plan B, an emergency contraceptive, as a behind-
212the-counter drug, again giving pharmacists an unusual role in its distribution.
Plan B is unique in that it is available without a prescription to women seventeen
213years or older, but only by prescription to younger women. Nevertheless, neither
group may purchase the drug off the shelf.214 The risk management strategy,
CARE, 215 requires that customers request Plan B directly from the pharmacist,
because the pharmacist must keep the drug "behind the counter.' '216 CARE has
some provisions that may be just as onerous as requiring a genetic test report to
dispense genetic-based drugs. The Plan B manufacturer must monitor compliance
with the age restrictions, educate providers about the age restrictions, track how
Plan B is being sold with anonymous shoppers if necessary, and report violators to
State Boards of Pharmacy. 17
Congress has also weighed in on how pharmacists may sell cold medications
that contain the same ingredients as the highly addictive drug methamphetamine.218
A product such as Sudafed, which contains these ingredients,219 must be sold from
behind the counter where it must be locked away until time of purchase,220 and the
seller--often a pharmacist-must deliver it directly into the purchaser's hand,22 1
keep a "logbook" of purchasers,222 check each purchaser's identification,223 and
212. Letter from Steven Galson, Director, Ctr. for Drug Evaluation & Research, to Joseph A.
Carrado, Vice President, Clinical Reg. Aff., Duramed Research, Inc. (Aug. 24, 2006), available at
http://www.accessdata.fda.gov/drugsatfda-docs/appletter/2006/021045s01 I ltr.pdf.
213. Press Release, U.S. Food & Drug Admin., Updated FDA Action on Plan B (Levonorgestrel)
Tablets (Apr. 22, 2009), available at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/
ucm149568.htm (informing the public that Plan B may be marketed to women seventeen years of age or
older without a prescription).
214. Memorandum from Steve Galson, Director, Ctr. for Drug Evaluation & Research on Plan B
(Aug. 24, 2006), available at http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafety
InformationforPatientsandProviders/ucm I 09782.pdf [hereinafter Galson Memorandum].
215. See Brittany L. Grimes, Note, The Plan B for Plan B: The New Dual Over-the-Counter and
Prescription Status of Plan B and Its Impact upon Pharmacists, Consumers, and Conscience Clauses,
41 GA. L. REV. 1395, 1415-16 (2007) (discussing the requirements of the CARE program).
216. Galson Memorandum, supra note 214.
217. Id.
218. See 21 U.S.C. § 830(d)-(e) (2006) (regulating the sale of ephedrine, pseudoephedrine, and
phenylpropanolamine). These substances, common ingredients in cough medicines, can be used to
manufacture methamphetamine. See Jean C. O'Connor et al., Developing Lasting Legal Solutions to the
Dual Epidemics of Methamphetamine Production and Use, 82 N.D. L. REV. 1165, 1166, 1171 (2006)
(referring to the substances in common cough medicines as "methamphetamine precursors").
219. See Patricia Stanley, Comment, The Combat Methamphetamine Epidemic Act: New Protection
or New Intrusion?, 39 TEX. TECH L. REV. 379, 391 (2007) (discussing a case involving the purchase of
Sudafed as evidence to convict for the possession of pseudoephedrine with the intent to manufacture
methamphetamine); Sudafed.com, Sudafed Nasal Decongestant Tablets, http://www.sudafed.com/
#adult/nasal/tablets (last visited Feb. 20, 2010) (identifying pseudoephedrine as the active ingredient).
220. § 830(e)(l)(A)(i).
221. Id. § 830(e)(l)(A)(ii).
222. Id. § 830(e)(1)(A)(iii)-(iv).
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limit the volume sold to any one person. 4 The burden of checking genetic test
reports may be relatively simple compared to the procedures necessary to sell
Sudafed.
2 5
D. Effective Means of Regulatory or Judicial Enforcement
The FDA does not have to rely solely on manufacturers to police the terms on
which pharmacists dispense a drug.226 If the drug is approved for only certain uses
consistent with a customer's genetic profile or is subject to a risk management
strategy that relies on the pharmacist to dispense only to those customers, to do
otherwise will probably be a breach of a duty of care exposing the pharmacist to
common law tort liability for any damages as a result of dispensing the drug.
227
The first duty would be to warn the customer of the risk of using the drug
without proof of the proper genotype.228 The most recent state law warning cases
holding a pharmacist liable for failure to warn were based upon whether the
plaintiff reasonably relied on the pharmacist's superior knowledge and skill.229
Some hold that a pharmacy assumes the risk of liability by advertising that its
services were "safe 230 or that it would check for contraindications.231 Yet whether
a pharmacist has a sufficient computer system may also determine whether she
"knew or should have known" of a danger to a customer.232 Computer systems
capable of providing pharmacists with sufficient notice of gene-based
contraindications may become the state of the art in the profession,233 and the lack
of such a system could subject a pharmacist to liability on that basis alone.234
223. Id. § 830(e)(I)(A)(iv)(I)(aa).
224. Id. § 830(d)(1).
225. Compare supra Part III.A (discussing the model for conditioning dispensing on genetic test
results), with supra notes 218-24 and accompanying text (discussing procedures necessary to sell
Sudafed).
226. See. e.g., Hooks SuperX, Inc. v. McLaughlin, 642 N.E.2d 514, 517 (Ind. 1994) (recognizing
that the special relationship between pharmacist and customer gives rise to a common law duty of care).
227. See infra notes 228-40 and accompanying text.
228. Cf Brian L. Porto, Annotation, Civil Liability of Pharmacists or Druggists for Failure to Warn
of Potential Drug Interactions in Use of Prescription Drug, 79 A.L.R.5th 409 (2000) (discussing federal
and state cases in which the courts have determined that pharmacists must wam their customers about
potential drug interactions).
229. See, e.g., Happel v. Wal-Mart Stores, Inc., 766 N.E.2d 1118, 1124 (Ill. 2002) ("By asking
customers about their drug allergies, the pharmacy ... engender[ed] reliance in the customer that the
pharmacy [would] .. .ensure that the customer [would] not receive a drug to which the customer is
allergic.").
230. Baker v. Arbor Drugs, Inc., 544 N.W.2d 727, 731 & n.l (Mich. Ct. App. 1996) (stating that a
pharmacy that advertises its use of a computer system to detect harmful drug interactions causes reliance
and assumes a duty of care).
231. Happel, 766 N.E.2d at 1124-25.
232. Id. at 1123, 1125; Baker, 544 N.W.2d at 731.
233. Cacciatore, supra note 20, at 113-14; see also Helen L. Figge, Enabling Medication Therapy
Management, 33 U.S. PHARMACIST (Sept. 18, 2008),
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Common law cases also impose duties such as refusing to dispense or calling
the physician where appropriate. 235 Refusing to dispense when the pharmacist is on
notice of a serious danger to the customer is well-recognized as a professional
duty,236 and with the appropriate computer technology, the pharmacist could be
considered always on notice of a genetically based contraindication every time a
customer attempts to fill such a prescription. 7 The standard of care would then
require a pharmacist to insist on seeing a genetic test prior to dispensing the
drug.238 Several courts also recognize a limited duty to call a physician to verify the
physician's intent to prescribe the drug in the dose ordered, when the pharmacist
should recognize it may be inappropriate. 239 Doing so would allow a pharmacist to
remind a physician of a genetic-based risk to a customer from the drug or the
prescribed dose.24°
The FDA might be better served by piggy-backing on the common law than it
would if Congress enacted legislation, such as the Medical Device Amendments
http://www.uspharmacist.com/content/d/pharmacy..and-technology/c/10975/ (suggesting technological
advances in pharmaceutical record-keeping and dispensing practices will play a critical role in the
emerging field of medication therapy management).
234. See Dooley v. Everett, 805 S.W.2d 380, 382-83 (Tenn. Ct. App. 1990) (quoting expert
testimony that the standard of care for pharmacists might include alerting patients of contraindications
when technology is available to help identify drug interactions); Cacciatore, supra note 20, at 114-15
(noting that "[wlhile no court has held that it is malpractice per se for a pharmacist" not to have a
sufficient computer system, a physician has been held liable for failing to do a sufficient literature
search).
235. See, e.g., Horner v. Spalitto, 1 S.W.3d 519, 523 (Mo. Ct. App. 1999).
236. Hooks SuperX, Inc. v. McLaughlin, 642 N.E.2d 514, 516-19 (Ind. 1994) (recognizing a duty to
a customer if the customer commits suicide as a result of having consumed excess amounts of a drug,
where the pharmacist is on notice that the customer is consuming the drug at a much faster rate than is
appropriate).
237. See Dooley, 805 S.W.2d at 382-85 (stating that a pharmacist has a duty to his customer to
exercise the standard of care required by the pharmacy profession in the same or similar communities,
which may include the use of computer technology).
238. Cf Hooks SuperX, Inc., 642 N.E.2d at 519 ("We are confident that the skilled pharmacists of
our state, particularly when aided with computerized customer information records, will be readily able
to determine when a prescription is being refilled at an unreasonably faster rate than the rate
prescribed.").
239. Homer, I S.W.3d at 522-24 (stating that a pharmacist's duty arises out of their unique skill set,
which allows them to identify a prescription that may harm a patient, and to contact the prescribing
physician to confirm or dispute a particular dose or drug). But see Gassen v. E. Jefferson Gen. Hosp.,
628 So.2d 256, 258-59 (La. Ct. App. 1993) (stating that a pharmacist has a duty to warn patients or
notify prescribing physicians of prescriptions that could seriously harm those patients but does not have
a duty to warn patients of hazardous side effects or to question a physician about the propriety of a
prescription in the absence of a substantial risk of serious harm).
240. Cf David W. Bates et al., The Impact of Computerized Physician Order Entry on Medication
Error Prevention, 6 J. AM. MED. INFORMATIcS Ass'N 313, 315 (1999) (showing that pharmacists who
monitored computerized medication entry systems eliminated more than eighty percent of medication
errors due to potential contraindications by alerting the prescribing physicians).
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Act,24' that would preempt state actions.242 The Supreme Court has held that the
Food, Drug, and Cosmetic Act 24 3 cannot be interpreted as providing a private right
of action to plaintiffs suing to recover for violations of FDA regulations, 244 but such
violations can be proof of a pharmacist's failure to fulfill her duty of care in state
court.
2 4 5
CONCLUSION
The FDA does not have to "go it alone" to protect consumers from drugs
inappropriately prescribed for their genotype.246 Legal, practical, and aspirational
developments in the pharmacy profession make pharmacists an ideal partner for
achieving this goal.247 If the FDA and pharmacy profession work together and
bring physicians into the process, in the long term the health care system and its
patients will enjoy the full benefits of pharmacogenomics and personalized
medicine.
241. Medical Device Amendments of 1976, Pub. L. No. 94-295, 90 Stat. 539 (codified as amended
in scattered sections of 21 U.S.C.).
242. Cf Riegel v. Medtronic, Inc., 128 S. Ct. 999, 1006-07 (2008) ("[T]he [Medical Device
Amendments] expressly pre-empt[] . . . state requirements different from, or in addition to, any
requirement applicable ... to the device under federal law .... ") (internal quotations omitted).
243. Federal Food, Drug, and Cosmetic Act, 21 U.S.C. §§ 301-399 (2006).
244. Merrell Dow Pharm., Inc. v. Thompson, 478 U.S. 804, 806-07 (1986). Merrell Dow held that
the alleged misbranding violation of the Food, Drug, and Cosmetic Act was not sufficiently
"substantial" based on Congress' failure to create a private action to grant federal question jurisdiction
to the district courts. Id. at 814. On the other hand, it does not challenge the plaintiffs' view that if
proved, violation of the regulation would establish breach of the standard of care and causation in a
products liability claim. See id. at 812-13 (refusing to address the question of whether a violation of the
federal regulation satisfies the element of the state claim). Failure to require a genetic test report prior to
dispensing a drug would be at least as, if not more, serious.
245. Cf Anne Erikson Haffner, Comment, The Increasing Necessity of the Tort System in Effective
Drug Regulation in a Changing Regulatory Landscape, 9 J. HEALTH CARE L. & POL'Y 365, 371-72
(2006) (arguing that compliance with labeling may be proof of the standard of care for physicians, but it
is not a complete defense).
246. See supra Part III.D.
247. See supra Part 1.
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